|
TSPYL4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.94449999832725E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.99130000003256E-06 |
| Normal-vs-Stage2 |
1.059870E-02 |
| Normal-vs-Stage3 |
1.91360038925836E-10 |
| Normal-vs-Stage4 |
3.15420001228972E-09 |
| Stage1-vs-Stage2 |
3.744800E-01 |
| Stage1-vs-Stage3 |
1.098010E-02 |
| Stage1-vs-Stage4 |
1.124260E-02 |
| Stage2-vs-Stage3 |
3.235800E-02 |
| Stage2-vs-Stage4 |
2.145700E-02 |
| Stage3-vs-Stage4 |
6.585000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.15909999878861E-08 |
| Normal-vs-AfricanAmerican |
3.089600E-02 |
| Normal-vs-Asian |
2.043200E-04 |
| Caucasian-vs-AfricanAmerican |
1.520040E-01 |
| Caucasian-vs-Asian |
4.590200E-01 |
| AfricanAmerican-vs-Asian |
4.538800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.06739994620852E-09 |
| Normal-vs-Female |
9.52479999982714E-07 |
| Male-vs-Female |
7.151700E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.83710000054316E-07 |
| Normal-vs-Age(41-60Yrs) |
1.44930000001153E-06 |
| Normal-vs-Age(61-80Yrs) |
1.05370001612926E-09 |
| Normal-vs-Age(81-100Yrs) |
7.244000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.907000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.548100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.362400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.878400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.084400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.049200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.63030000400033E-08 |
| Classical-VS-Follicular |
2.669400E-01 |
| Classical-VS-Other |
5.211000E-01 |
| Classical-VS-Normal |
4.63989999999193E-06 |
| Tall-VS-Follicular |
3.954800E-04 |
| Tall-VS-Other |
2.462600E-01 |
| Tall-VS-Normal |
2.77666778458752E-13 |
| Follicular-VS-Other |
8.105200E-01 |
| Follicular-VS-Normal |
1.68981999999485E-05 |
| Other-VS-Normal |
1.352000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.64839999988931E-07 |
| Normal-vs-N1 |
2.51220000357932E-09 |
| N0-vs-N1 |
3.004400E-02 |
|
|
